The Lynx Group
Cholangiocarcinoma News

Lenvatinib plus Pembrolizumab for Patients with Previously Treated Biliary Tract Cancers in the Multicohort Phase 2 LEAP-005 Study

2021 Year in Review: Cholangiocarcinoma — December 17, 2021

Results of the phase 2 LEAP-005 study suggest that lenvatinib plus pembrolizumab shows promising antitumor activity and manageable toxicity in previously treated patients with advanced biliary tract cancers.

The nonrandomized, open-label, multicohort phase 2 LEAP-005 study ( Identifier: NCT03797326) evaluated the efficacy and safety of the antiangiogenic multikinase inhibitor lenvatinib in combination with the anti–PD-1 immune checkpoint inhibitor pembrolizumab in patients with previously treated advanced solid tumors. Results from the biliary tract cancer (BTC) cohort of LEAP-005 were presented at the 2021 American Society of Clinical Oncology Annual Meeting.

The LEAP-005 study enrolled patients aged ≥18 years with histologically or cytologically documented metastatic and/or unresectable BTCs with disease progression after 1 prior line of therapy, measurable disease per RECIST version 1.1, Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1, and a tissue sample evaluable for PD-L1 expression. Eligible patients received lenvatinib 20 mg once daily plus pembrolizumab 200 mg once every 3 weeks for up to 35 cycles (approximately 2 years), or until confirmed disease progression, unacceptable toxicity, or withdrawal of consent. Treatment with lenvatinib could continue beyond 2 years in patients who were experiencing clinical benefit. Primary end points of the study included overall response rate (ORR) by blinded independent central review and safety. Secondary end points included disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Tumor imaging was performed once every 9 weeks from treatment initiation for 54 weeks, then once every 12 weeks to week 102, and once every 24 weeks thereafter. Data cutoff was April 10, 2020.

A total of 31 patients were included in the BTC cohort. The median participant age was 65 years. The majority of patients were female (58%), 55% had an ECOG PS of 1, and 90% had received 1 prior line of therapy. At data cutoff, the ORR was 10%, which included 3 partial responses. The DCR was 68%, including 18 participants with stable disease. The median DOR was 5.3 months (range, 2.1+ to 6.2 months). The median PFS was 6.1 months, and the median OS was 8.6 months.

Treatment-related adverse events (TRAEs) in the safety population (n = 31) were reported in 30 patients (97%), with the most common all-grade TRAEs (≥32%) including hypertension (42%), dysphonia (39%), diarrhea (32%), fatigue (32%), and nausea (32%). Grade 3/4 TRAEs were reported in 15 patients (48%); immune-mediated adverse events occurred in 14 participants (45%). No treatment-related deaths were reported. Overall, 2 (6%) patients discontinued treatment due to TRAEs of myocarditis or pyrexia.

Based on these results, the investigators concluded that the combination of lenvatinib plus pembrolizumab showed promising antitumor activity and manageable toxicity in patients with advanced BTC who had received 1 line of prior therapy. Enrollment in the BTC cohort of the LEAP-005 study thus has been expanded to 100 patients to further define the role played by lenvatinib plus pembrolizumab in the treatment of BTC.

Source: Villanueva L, Lwin Z, Chung HC, et al. Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study. J Clin Oncol. 2021;39(suppl_3):321-321.

Related Items

A Phase 1/2 Study of the Safety and Efficacy of the Arginase Inhibitor INCB001158 plus Chemotherapy in Patients with Advanced Biliary Tract Cancer
2021 Year in Review: Cholangiocarcinoma
Results of an open-label, phase 1/2 study indicate that addition of INCB001158 to the standard gemcitabine/cisplatin backbone was tolerable, did not result in significant additional toxicity, and showed modest clinical activity in the biliary tract cancers cohort.
Zanidatamab (ZW25) in HER2-Positive Biliary Tract Cancers: Results from a Phase 1 Study
2021 Year in Review: Cholangiocarcinoma
Results from a first-in-human, phase 1 study have shown that the bispecific HER2-targeted antibody zanidatamab is well-tolerated and has antitumor activity in patients with HER2-overexpressing biliary tract cancers.
Phase 2a MyPathway Results of Pertuzumab plus Trastuzumab for the Treatment of HER2-Positive Metastatic Biliary Tract Cancer
2021 Year in Review: Cholangiocarcinoma
Results of an ongoing, phase 2a, multiple-basket study (MyPathway) showed that dual HER2-targeted therapy with pertuzumab plus trastuzumab was well-tolerated in patients with previously treated HER2-positive metastatic biliary tract cancer.
Liposomal Irinotecan in Combination with 5-Fluorouracil and Leucovorin for Patients with Metastatic Biliary Tract Cancer After Progression on Gemcitabine plus Cisplatin: A Multicenter, Comparative, Randomized, Phase 2b Study (NIFTY)
2021 Year in Review: Cholangiocarcinoma
Results of the NIFTY trial demonstrated that liposomal irinotecan plus 5-fluorouracil and leucovorin significantly improved efficacy outcomes compared with 5-fluorouracil plus leucovorin alone in patients with biliary tract cancer who progressed on prior gemcitabine/cisplatin, with a manageable adverse event profile.
Liposomal Irinotecan plus 5-Fluorouracil/Leucovorin or Gemcitabine/Cisplatin in Patients with Advanced Biliary Tract Cancer (NIFE Trial)
2021 Year in Review: Cholangiocarcinoma
The phase 2 NIFE study compared a liposomal irinotecan plus fluorouracil and leucovorin regimen with standard-of-care gemcitabine/cisplatin in patients with advanced biliary tract cancer.
Does Adjuvant Chemoradiation Benefit Patients with Lymph Node–Positive Biliary Tract Cancer? A Secondary Analysis of SWOG S0809
2021 Year in Review: Cholangiocarcinoma
Results of the secondary analysis of the SWOG S0809 trial indicate that nodal status did not impact survival outcomes achieved with adjuvant chemoradiation postresection in patients with extrahepatic CCA or gallbladder cancer.
Role of ctDNA to Predict Risk for Recurrence Following Potentially Curative Resection of Biliary Tract and Pancreatic Malignancies
2021 Year in Review: Cholangiocarcinoma
Results of a pilot study demonstrate the feasibility of ctDNA testing and the prognostic value of ctDNA following potentially curative resection in patients with pancreatic/biliary tract malignancies.
Efficacy and Safety of Nab-Paclitaxel plus Gemcitabine/Cisplatin in Korean Patients with Advanced Biliary Tract Cancers
2021 Year in Review: Cholangiocarcinoma
Real-world retrospective evidence from Korean patients with advanced biliary tract cancer indicates that efficacy and safety with nab-paclitaxel plus gemcitabine/cisplatin combination were consistent with those previously reported in clinical trials.
First-Line Immunotherapy plus Chemotherapy Significantly Improves Survival in Advanced Biliary Tract Cancer
Web Exclusives
On October 25, 2021, AstraZeneca announced high-level positive results from the phase 3 clinical trial TOPAZ-1, demonstrating that adding the immunotherapy durvalumab (Imfinzi) to first-line standard-of-care chemotherapy leads to a statistically significant and clinically meaningful overall survival (OS) benefit versus chemotherapy alone in patients with advanced biliary tract cancer.
Hot Topics in Cholangiocarcinoma and Biliary Tract Cancers: ASCO Highlights
September/October 2021, Vol 2, No 3
At the CCA Summit during the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO), Mitesh J. Borad, MD, Associate Professor of Medicine, Mayo Clinic, Phoenix, AZ, reviewed some of the key topics presented at ASCO 2021 related to cholangiocarcinoma (CCA) and other biliary tract cancers. Before turning to the specific presentations, Dr Borad welcomed the May 28, 2021, FDA approval of infigratinib (Truseltiq) for patients with advanced or metastatic CCA and FGFR2 fusions or rearrangements. Infigratinib follows pemigatinib (Pemazyre) as the second targeted therapy now available for this patient population.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: